×

Will Clinton's 'price gouging' comments hit biotech?

6:24 PM ET Tue, 22 Sept 2015

While Hillary Clinton's proposal of a monthly cap on prescription drugs will create near-term volatility in biotech shares, the policy is unlikely to be implemented, says Michael Yee, biotech analyst at RBC Capital Markets.